Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

Virtual Diagnosis?

The AIDS virus’s ability to quickly mutate and become resistant to new drugs makes it difficult for doctors to choose medications that will work. Researchers at Virco Group in Oxford, England, have created a new tool to give doctors better information about viral drug resistance, allowing them to design effective therapies. Called Virtual Phenotype, the analysis takes the genetic code of a patient’s HIV strain and predicts the drugs it will be resistant to. The system, one of the earliest examples of pharmacogenomics in action, reportedly provides the first quantitative analysis of viral drug resistance. The analysis is quicker than actual phenotype testing, which involves growing virus and screening it with drugs, and costs up to three times less. Virco is developing similar databases for cancer and hepatitis B.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.